Landry Robert E — SEC insider filings
SEC reporting owner CIK 1585160. 36 insider filings on record with FilingPulse; latest filed 2026-09-15.
Transaction summary — filings shown
Covers all 36 filings on record, filed 2020-12-11 to 2026-09-15. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 120 legs across 17 filings — 14,702 shares, $9,294,657 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 128.
- Largest priced transaction: sale of 1,226 shares @ $733.52 ($899,296) in REGENERON PHARMACEUTICALS, INC., filed 2022-04-11.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| REGENERON PHARMACEUTICALS, INC. (REGN) | EVP Finance CFO | 29 | — | 118 legs · 12,702 sh · $9,147,867 | 120 |
| CYTOKINETICS INC (CYTK) | Director | 5 | — | 2 legs · 2,000 sh · $146,790 | 5 |
| Zymeworks Inc. (ZYME) | Director | 2 | — | — | 3 |
Insider filings — Landry Robert E
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-15 | 4 | CYTOKINETICS INC (CYTK) | Sale (S): 1,000 @ $72.13 | EDGAR |
| 2026-09-11 | 4 | CYTOKINETICS INC (CYTK) | Sale (S): 1,000 @ $74.66 | EDGAR |
| 2026-05-27 | 4 | CYTOKINETICS INC (CYTK) | Grant/award (A): 2,851 @ $0 · Grant/award (A): 4,301 (derivative) @ $0 | EDGAR |
| 2026-01-12 | 4 | Zymeworks Inc. (ZYME) | Grant/award (A): 11,500 (derivative) @ $0 · Grant/award (A): 7,700 (derivative) @ $0 | EDGAR |
| 2025-08-12 | 4 | Zymeworks Inc. (ZYME) | Grant/award (A): 62,000 (derivative) @ $0 | EDGAR |
| 2025-05-14 | 4 | CYTOKINETICS INC (CYTK) | Grant/award (A): 7,333 @ $0 · Grant/award (A): 10,880 (derivative) @ $0 | EDGAR |
| 2025-02-11 | 4 | CYTOKINETICS INC (CYTK) | Grant/award (A): 25,538 (derivative) @ $0 | EDGAR |
| 2024-02-06 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Option exercise (M): 400 @ $378.98 · Tax withholding (F): 281 @ $956.65 · Option exercise (M): 400 (derivative) @ $0 | EDGAR |
| 2024-02-02 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Option exercise (M): 400 @ $378.98 · Tax withholding (F): 282 @ $953.42 · Option exercise (M): 400 (derivative) @ $0 | EDGAR |
| 2024-01-25 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Option exercise (M): 1,100 @ $378.98 · Tax withholding (F): 776 @ $948.50 · Option exercise (M): 500 @ $378.98 · Tax withholding (F): 352 @ $951.26 · Option exercise (M): 1,100 (derivative) @ $0 · Option exercise (M): 500 (derivative) @ $0 | EDGAR |
| 2024-01-18 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Option exercise (M): 500 @ $378.98 · Tax withholding (F): 354 @ $932.34 · Option exercise (M): 500 (derivative) @ $0 | EDGAR |
| 2024-01-17 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Option exercise (M): 800 @ $378.98 · Tax withholding (F): 568 @ $928.18 · Option exercise (M): 800 (derivative) @ $0 | EDGAR |
| 2024-01-08 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Option exercise (M): 500 @ $378.98 · Tax withholding (F): 342 @ $917.05 · Option exercise (M): 500 (derivative) @ $0 | EDGAR |
| 2024-01-04 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Option exercise (M): 650 @ $378.98 · Tax withholding (F): 421 @ $888.34 · Option exercise (M): 1,100 @ $378.98 · Tax withholding (F): 688 @ $912.30 · Option exercise (M): 650 (derivative) @ $0 · Option exercise (M): 1,100 (derivative) @ $0 | EDGAR |
| 2023-12-29 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Option exercise (M): 750 @ $378.98 · Tax withholding (F): 542 @ $872.21 · Option exercise (M): 850 @ $378.98 · Tax withholding (F): 612 @ $884.88 · Option exercise (M): 750 (derivative) @ $0 · Option exercise (M): 850 (derivative) @ $0 | EDGAR |
| 2023-12-14 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Tax withholding (F): 6,381 @ $856.71 · Option exercise (M): 1,000 @ $378.98 · Tax withholding (F): 723 @ $871.12 · Option exercise (M): 1,000 (derivative) @ $0 | EDGAR |
| 2023-12-12 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Tax withholding (F): 1,013 @ $843.79 · Tax withholding (F): 669 @ $844.09 · Tax withholding (F): 2,552 @ $844.09 | EDGAR |
| 2023-08-25 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Sale (S): 223 @ $844 | EDGAR |
| 2023-03-29 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Option exercise (M): 800 @ $381.92 · Tax withholding (F): 589 @ $825.17 · Option exercise (M): 3,000 @ $378.98 · Tax withholding (F): 2,204 @ $825.17 · Sale (S): 39 @ $819.47 · Sale (S): 50 @ $820.46 · +16 more | EDGAR |
| 2023-02-07 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Sale (S): 739 @ $764.50 · Option exercise (M): 3,000 @ $381.92 · Tax withholding (F): 2,248 @ $774.29 · Sale (S): 51 @ $783.05 · Sale (S): 113 @ $784.27 · Sale (S): 78 @ $785.88 · +12 more | EDGAR |
| 2022-12-20 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Grant/award (A): 3,853 @ $0 · Grant/award (A): 14,222 (derivative) @ $0 | EDGAR |
| 2022-12-12 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Option exercise (M): 3,000 @ $381.92 · Tax withholding (F): 2,261 @ $768.54 · Tax withholding (F): 492 @ $753.28 · Option exercise (M): 3,000 (derivative) @ $0 | EDGAR |
| 2022-12-02 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Option exercise (M): 2,500 @ $381.92 · Tax withholding (F): 1,890 @ $760.35 · Sale (S): 582 @ $756.50 · Sale (S): 16 @ $759.90 · Sale (S): 12 @ $760.19 · Option exercise (M): 2,500 (derivative) @ $0 | EDGAR |
| 2022-11-02 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Option exercise (M): 2,000 @ $381.92 · Tax withholding (F): 1,518 @ $751.24 · Sale (S): 1 @ $750 · Sale (S): 40 @ $753.23 · Sale (S): 80 @ $754.39 · Sale (S): 81 @ $755.46 · +7 more | EDGAR |
| 2022-10-18 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Option exercise (M): 1,500 @ $381.92 · Tax withholding (F): 1,142 @ $743.78 · Sale (S): 358 @ $739.50 · Option exercise (M): 1,500 (derivative) @ $0 | EDGAR |
| 2022-04-11 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Option exercise (M): 1,500 @ $399.66 · Tax withholding (F): 1,175 @ $716.09 · Sale (S): 16 @ $724.33 · Sale (S): 30 @ $728.77 · Sale (S): 16 @ $729.67 · Sale (S): 44 @ $733.38 · +22 more | EDGAR |
| 2022-04-01 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Option exercise (M): 1,500 @ $399.66 · Tax withholding (F): 1,184 @ $700.99 · Sale (S): 301 @ $695.50 · Sale (S): 15 @ $701.98 · Option exercise (M): 1,500 (derivative) @ $0 | EDGAR |
| 2022-03-30 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Option exercise (M): 1,250 @ $555.67 · Tax withholding (F): 1,134 @ $685.26 · Option exercise (M): 1,250 @ $555.67 · Tax withholding (F): 1,134 @ $685.26 · Option exercise (M): 4,000 @ $399.66 · Tax withholding (F): 3,183 @ $685.26 · +23 more | EDGAR |
| 2022-03-23 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Sale (S): 300 @ $693 · Option exercise (M): 400 @ $381.92 · Tax withholding (F): 312 @ $691.31 · Option exercise (M): 400 (derivative) @ $0 | EDGAR |
| 2022-03-18 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Sale (S): 300 @ $677 · Sale (S): 83 @ $686 · Option exercise (M): 365 @ $381.92 · Tax withholding (F): 286 @ $682.50 · Option exercise (M): 365 (derivative) @ $0 | EDGAR |
| 2021-12-14 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Option exercise (M): 1,500 @ $555.67 · Tax withholding (F): 1,384 @ $664.34 · Tax withholding (F): 697 @ $664.34 · Sale (S): 116 @ $662.50 · Option exercise (M): 1,500 (derivative) @ $0 | EDGAR |
| 2021-12-10 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Grant/award (A): 3,971 @ $0 · Option exercise (M): 4,250 @ $399.66 · Tax withholding (F): 3,469 @ $657.11 · Sale (S): 2 @ $656.46 · Sale (S): 50 @ $657.53 · Sale (S): 11 @ $658.52 · +15 more | EDGAR |
| 2021-11-18 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Option exercise (M): 3,750 @ $399.66 · Tax withholding (F): 3,069 @ $651.97 · Sale (S): 681 @ $645.08 · Option exercise (M): 3,750 (derivative) @ $0 | EDGAR |
| 2021-09-01 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Option exercise (M): 1,000 @ $555.67 · Tax withholding (F): 917 @ $675.03 · Option exercise (M): 1,000 (derivative) @ $0 | EDGAR |
| 2021-08-10 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Option exercise (M): 2,000 @ $381.92 · Tax withholding (F): 1,636 @ $607.51 · Sale (S): 1 @ $610.85 · Sale (S): 36 @ $612.97 · Sale (S): 1 @ $613.79 · Sale (S): 66 @ $614.70 · +16 more | EDGAR |
| 2020-12-11 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Grant/award (A): 1,930 @ $0 · Grant/award (A): 19,950 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-12-09 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1585160 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs